PerkinElmer
check quantity

VIEWPLATE-384 TC, White, clear bottom, sterile TC treated, Case of 40

384-well tissue culture treated (TC-treated) sterile ViewPlate microplate with white well walls and a clear bottom for viewing plates under a microscope or bottom reading measurements.

Part Number
List Price
Your Price
Quantity
6007480
587.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

Our ViewPlate microplates are engineered for bottom reading systems. This high quality microplate can be utilized in your cell based assay for superior results.

Leveraging years of assay and instrument experience in plate detection, PerkinElmer designs better microplates for better performance that guarantees better results for all PerkinElmer applications.

Specifications

Automation Compatible Yes
Coating Treatment TC-treated, Sterile
Color White/Clear Bottom
Detection Method Time-Resolved Fluorescence (TRF), Luminescence, Alpha, Radiometric
Material Polystyrene
Product Brand Name ViewPlate
Shipping Condition Ambient
Sterile Yes
Unit Size Case of 40
Wells Number 384 well plate
Resources, Events & More
  • All

Application Note

Measuring PD-L1 Expression in Breast Cancer Cell Lines with AlphaLISA

Too many candidates, too little time. The lack of robust, rapid, high-throughput assays to identify and qualify potential therapeutic targets in areas such as cancer research continues to cost valuable time. What if you could increase assay throughput without compromising sensitivity, obtain more data points from each sample and eliminate tedious wash steps? Find out how AlphaLISA® assay technology, combined with the EnVision® multimode plate reader, provides a fast, powerful, homogeneous platform for screening potential inhibitors of PD-L1 (a protein associated with breast cancer tumor cells) expression in human cells.

PDF 4 MB
Measuring PD-L1 and PD-1 Expression in Human Cells with LANCE Ultra TR-FRET

Immuno-oncology is an exciting area within cancer research and among the most promising approaches to activating therapeutic antitumor immunity is through the blockade of immune checkpoints. The programmed cell death-1 (PD-1) immune checkpoint pathway is a negative regulator of T cell immune function. When PD-1 is bound to programmed cell death-ligand 1 (PD-L1), T cell response is suppressed. Many tumor cells escape anti-tumor immunity through their expression of Programmed Death Ligand 1 (PD-L1 or B7-H1), which interacts with T cell-expressed PD-1 and results in T cell apoptosis. PD-L1 expression has been studied in multiple different cancers. While several anti-PD-1 or PD-L1 monoclonal antibodies that block the PD-1/ PD-L1 complex formation have been developed to date, there remains a need for more robust, rapid, high-throughput assays to identify and qualify novel inhibitors of PD-1/PD-L1 binding and assays to detect expression levels of both binding partners. Find out how LANCE® Ultra Technology provides a fast, powerful, homogeneous platform for identifying and characterizing endogenous PD-L1 and PD-1 expression in human cells.

PDF 4 MB

Poster

Running an Aequorin Cell-Based Luminescent Assay on the FLIPR TETRA

We have shown here that signal intensity for the selected catalog aequorin cell lines is strong enough to allow its measurement by the non-luminescence dedicated FLIPR

PDF 270 KB